Episode 26 — 09 June 2026

CHMP's May approvals reveal a structural shift toward rare disease development while the Critical Medicines Act introduces mandatory supply chain transparency requirements. AI maintains its dominance in HEOR methodology as NICE expands cardiovascular and digital health guidance.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast